

CURRICULUM VITAE  
NICKOLAS D. ZALLER

The Miriam Hospital  
Immunology Center  
164 Summit Ave  
RISE/CFAR Building  
Providence, RI 02096  
(401) 793-4875  
nzaller@lifespan.org

EDUCATION

Undergraduate	Kansas University, Microbiology and East Asian Studies, Bachelor of Arts 1999
Graduate	Johns Hopkins Bloomberg School of Public Health, 2000-2004, PhD 2004
Post Graduate	Brown University Initiative in Spatial Structures in the Social Sciences (S4) Summer Institute, 2006.  2007 National Institutes of Health Summer Institute on the Design and Development of Community-Based Participatory Research in Health

RECENT PROFESSIONAL EXPERIENCE

**The Miriam Hospital**  
Research Associate, 2008-

**The Miriam Hospital**  
The Samuel and Chester Esther Immunology Center, Providence, RI  
Project Director, Project Vista (Center for Substance Abuse Treatment: TI15870) (2004-08)  
Project Director, Caring for HIV/Hepatitis C in Methadone Programs (CHAMP) Study, Roche Laboratories, Inc, (2005-2008)  
The Samuel and Chester Esther Immunology Center, Providence, RI  
Post-doctoral T 32 Research Fellow (2006-2007)

**Rhode Island College**  
Adjunct Professor of Psychiatry (2011-)  
Instructor: Drugs, Society and Chemical Dependency  
2011-

**Johns Hopkins Bloomberg School of Public Health**

Department of International Health, Regional Centers for Disease Control, Baltimore, MD and Urumqi, Xinjiang, China  
Investigator (2002-2004).

#### APPOINTMENTS

##### **The Alpert Medical School of Brown University, Providence RI**

Assistant Professor in Medicine (Research), (2008-)

##### **Rhode Island College**

Adjunct Professor of Psychiatry (2011-)

##### **Mayor David N. Cicilline's Substance Abuse Prevention Council**

Chair, 2007-

#### BOARD MEMBERSHIP

**Rhode Island College Institute for Addiction and Recovery** (2009- )

**Rhode Island Public Health Association** (2010- )

**New England Addiction Technology Transfer Center (ATTC)** (2010-)

#### POSTGRADUATE HONORS AND AWARDS

Fulbright Fellowship, Beijing University 1999.

Carl E. Taylor Award in Bioethics, Johns Hopkins

Bloomberg School of Public Health, 2003.

#### ORIGINAL PEER-REVIEWED PUBLICATIONS

1. **Zaller N**, Nelson K, Aladashvili M, Badrize N, del Rio C and Tsertsvadze T. Risk Factors for HCV Infection Among Blood Donors in Georgia. *Eur J of Epidemiol.* 2004; 19(6): 547-553.
2. **Zaller N**, Nelson K, Ness P, Wen G, Bai X and Shan H. Knowledge, attitude and practice survey regarding blood donation in a Northwestern Chinese city. *Transfusion Medicine.* 2005; 15: 277-286.
3. **Zaller N**, Noak A, Poshkus M, McDonald L and Rich J. The Overlapping Epidemics of Viral hepatitis/HIV, Addiction and Incarceration: The Current Situation in Rhode Island. *Rhode Island Medicine and Health.* 2005; 88(12): 424-27.
4. **Zaller N**, Nelson K., Ness P, Wen G, Kewir T, Bai X and Shan H. Demographic Characteristics and Risks for Transfusion Transmissible Infection Among Blood Donors at the Largest Blood Center in Xinjiang Autonomous Region, PRChina.

*Transfusion*. 2006; 46(2): 265-71.

5. Beckwith C, **Zaller N**, Rich, J. Addressing the HIV Epidemic Through Quality Correctional Healthcare. *Criminology & Public Policy* 2006; 5(1): 149-156.
6. Beckwith, C Moreira C, Aboshady H, **Zaller N**, Rich JD and Flanigan TP. A success story: HIV prevention for injection drug users in Rhode Island. *Substance Abuse Treatment, Prevention and Policy*. 2006; 1(34)
7. **Zaller ND**, Thurmond P, et al. Linkage to methadone treatment from acute opiate detoxification treatment. *Journal of Opioid Management*. 2007; 2(6): 341-346.
8. **Zaller N**, Thurmond P, et al. Limited Spending: An Analysis of Correctional Expenditures on Antiretrovirals for HIV infected Prisoners. *Public Health Reports*. 2007; 121(1): 49-54.
9. Brim N, **Zaller N**, et al. Twinrix Vaccination Schedules Among Injection Drug Users: a Review. *Expert Opinions in Biological Therapies* 2007; 7(3): 379-89.
10. Rich JD, Hogan JW, Wolf F, DeLong A, **Zaller N**, et al. Lower Syringe Sharing and Re-Use After Syringe Legalization in Rhode Island. *Drug and Alcohol Dependence* 2007; 89: 292-97.
11. Beckwith C, **Zaller N** and Flanigan T. HIV counseling and testing of injection drug users: The objective has not yet been met. *American J of Public Health*. 2007; 97(7): 1161.
12. **Zaller N**. Drug Court as an Alternative to Incarceration. *Rhode Island Medicine and Health* 2007; 90(5): 154-56.
13. **Zaller N**, Gillani F and Rich JD. A Model of Integrated Primary Care for HIV Positive Patients with Underlying Substance Use and Mental Illness. *AIDS Care* 2007; 19(9): 1128-33.
14. **Zaller N**, DaWalt M, et al. Routine HIV Testing in US Jails and Prisons: Seizing the opportunity to provide healthcare and protect public health. *Lancet Infectious Diseases*, 2007; 7(7): 440-41
15. **Zaller N**, Taylor LE, et al. Hepatitis C in Correctional Institutions. *Current Hepatitis Reports*, 2007; 6(3): 114-117.
16. Boutwell A, Nijhawan A, **Zaller N** and Rich JD. Arrested on Heroin: a national opportunity. *Journal of Opioid Management*. 2007; 3(6): 328-332.
17. **Zaller N**, Holmes L, et al. Linkage to Treatment and Supportive Services Among HIV(+) Ex-Offenders. *Journal of Healthcare for the Poor and Underserved*, 2008;

May;19(2):522-31.

18. Mitty J, Bazerman L, Slewyn K, Beckwith C, **Zaller, N** and Rich J. Decrease in the Proportion of Injection Drug Related HIV/AIDS in Massachusetts, New York, Connecticut and Rhode Island. *The AIDS Reader*. 2008; 18(12):596-600. PMID: PMC2936235.
19. **Zaller ND**, Bazazi AR, Velazquez V and Rich JD. Attitudes toward Methadone Among Out of Treatment Minority Injection Drug Users: Implications for Health Disparities. *Int. J. Environ. Res. Public Health* 2009; 6: 787-797. PMID: 19440415, PMID: PMC2672350
20. Nunn A, **Zaller N**, et al Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a Nationwide Survey. *Drug Alcohol Depend.* 2009 Jul 20. 105(1-2):83-8. PMID: PMC2743749.
21. Wakeman SE, **Zaller N**, et al. HIV among marginalized populations in Rhode Island. *Med Health R I.* 2009; 92(7):244-6. PMID : PMC2851234.
22. Gillani FS, **Zaller N**, et al. Changes in demographics and risk factors among persons living with HIV in an academic medical center from 2003-2007. *Med Health R I.* 2009;92(7):237-40. PMID: PMC3028515.
23. Nguyen BT, **Zaller N**. Pharmacy provision of emergency contraception to men: a survey of pharmacist attitudes in Rhode Island. *J Am Pharm Assoc (2003)*. 2010 Jan-Feb;50(1):17-23. PMID: 20097635
24. Nguyen BT, **Zaller N**. Male access to over-the-counter emergency contraception survey of acceptability and barriers in Providence, Rhode Island. *Womens Health Issues.* 2009 Nov-Dec;19(6):365-72. PMID: 19879451
25. Flanigan TP, **Zaller N**, Taylor L, Beckwith C, Kuester L, Rich J, Carpenter CC. HIV and infectious disease care in jails and prisons: breaking down the walls with the help of academic medicine. *Trans Am Clin Climatol Assoc.* 2009;120:73-83.
26. McKenzie M, Nunn A, **Zaller ND**, Bazazi AR, Rich JD. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. *J Opioid Manag.* 2009 Jul-Aug;5(4):219-27. PMID: 19736902, PMID: PMC2936228.
27. Nunn A, **Zaller N**, Dickman S, Nijhawan A, Rich JD. Improving access to opiate addiction treatment for prisoners. *Addiction.* 2010 Jul;105(7):1312-3.
28. **Zaller N**, Yokell M, et al. An adverse event associated with a change in nonprescription syringe sales. *J of the Am Pharm Assoc.* 2010 Sep-Oct;50(5):619-22. PMID: PMC3008769.

29. **Zaller N**, Fu J, et al. The impact of financial discharge from methadone maintenance therapy on incarceration. *J Opioid Management*. 2010 Sep-Oct;6(5):365-70. PMID: PMC3028516.
30. Beckwith C, **Zaller N**, Fu J, Montague BT, and Rich JD. Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. *J Acquir Immune Defic Syndr*. 2010 Dec 1;55 Suppl 1:S49-55. PMID : PMC3017345.
31. Flanigan T, **Zaller N**, Beckwith CG, et al. Testing for HIV, Sexually Transmitted Infections, and Viral Hepatitis in Jails: Still a Missed Opportunity for Public Health and Prevention. *JAIDS*. 55: Suppl 2: S78-S83.
32. Bazazi AR, **Zaller N**, Fu JJ and Rich JD. Preventing opiate overdose deaths: examining objections to take-home naloxone. *J Health Care Poor Underserved*. 2010; 21(4): 1108-1113. PMID: PMC2851239.
33. **Zaller N**, Jeronimo A, et al, Bratberg J, et al. Pharmacist and Pharmacy Staff Experiences with Non-Prescription (NP) Sale of Syringes and Attitudes Toward Providing HIV Prevention Services for Injection Drug Users (IDUs) in Providence, RI. *J of Urban Health*. 2010 Dec;87(6):942-53.
34. Taylor LE, Bowman SE, Chapman S, **Zaller N**, Stein MD, Cioe PA, Maynard MA, McGovern BH. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. *Drug Alcohol Depend*. 2010 Dec 20.
35. **Zaller N**, Fu J, Nunn A, et al. Linkage to Care for HIV-Infected Heterosexual Men in the United States. *CID*. Jan 2011 15;52 Suppl 2:S223-30.
36. Bazazi AR, Yokell M, Fu JJ, Rich JD, **Zaller ND**. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. *J Addict Med*. 2011 Sep;5(3):175-80.
37. Green TC, **Zaller N**, Rich J, et al. Revisiting Paulozzi et al.'s "Prescription drug monitoring programs and death rates from drug overdose". *Pain Med*. 2011 Jun;12(6):982-5.
38. Yokell MA, **Zaller ND**, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. *Curr Drug Abuse Rev*. 2011 Mar 1;4(1):28-41.
39. Flanigan TP, **Zaller N**, Beckwith CG, et al. Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: still a missed opportunity for public health and HIV prevention. *J Acquir Immune Defic Syndr*. 2010 Dec;55 Suppl 2:S78-83.

40. Nunn A, **Zaller N**, Cornwall A, et al. Low perceived risk and high HIV prevalence among a predominantly African American population participating in Philadelphia's Rapid HIV testing program. *AIDS Patient Care STDS*. 2011 Apr;25(4):229-35.
41. Cornwall AH, **Zaller N**, Warren O, et al. A pilot study of emergency medical technicians' field assessment of intoxicated patients' need for ED care. *Am J Emerg Med*. 2011 Nov 3. [Epub ahead of print]
42. Mayer KH, Ducharme R, **Zaller N**, et al. Unprotected Sex, Underestimated Risk, Undiagnosed HIV and Sexually Transmitted Diseases Among Men Who Have Sex With Men Accessing Testing Services in a New England Bathhouse. *J Acquir Immune Defic Syndr*. 2011 Oct 24. 59(2):194-8
43. Green TC, **Zaller N**, et al. Revisiting Paulozzi et al.'s "Prescription drug monitoring programs and death rates from drug overdose". *Pain Med*. 2011 Jun;12(6):982-5
44. **Zaller N**, Yokell M, et al. Syringe Acquisition Experiences and Attitudes among Injection Drug Users Undergoing Short-Term Opioid Detoxification in Massachusetts and Rhode Island. *J Urban Health*. 2012 Mar 19. [Epub ahead of print]
45. Yokell M, **Zaller N**, et al. Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose. *J Opioid Manag*. 2012 Jan-Feb;8(1):63-6
46. **Zaller N**, Yokell M et al. Reported Experiences During Syringe Purchases in Providence, Rhode Island: Implications for HIV Prevention. *J Healthcare for the Poor and Underserved*. *In press*.

#### MEMBERSHIP IN SOCIETIES

Phi Beta Kappa  
American Public Health Association

#### BOOK CHAPTERS

1. Nijhawan A, **Zaller N**, et al. Interventions with incarcerated persons. In *HIV Prevention: A Comprehensive Approach*. Eds. Mayer KH and Pizer HF. Elsevier, Inc: London. 2009.

#### ABSTRACTS

1. **Zaller N**, Nelson K., Ness P, Wen G, Kewir T, Bai X and Shan H. 2004. Demographic and Donor Characteristics Among Blood Donors in Northwest China. American Association of Blood Banks (AABB) Annual Meeting, Oct 22-26, Baltimore, MD.

2. **Zaller N**, Nelson K, Ness P, Wen G, Bai X and Shan H. 2004. Motivations and Inhibitions Regarding Blood Donation in Northwest China. American Association of Blood Banks (AABB) Annual Meeting, Oct 22-26, 2008, Baltimore, MD.
3. Davidson A, **Zaller N**, Dukhovlina E, Toussova O, Niccolai L, Heimer R, and Kozlov R. HIV Serostatus Disclosure Practices and Attitudes among HIV Infected Patients in St. Petersburg, Russia. International AIDS Conference (IAC) Annual Meeting, August 3-8, 2008, Mexico City, Mexico.
4. Bowman S, McGovern B, Chapman S, **Zaller N**, et al, HCV Treatment for HIV/HCV Coinfected Genotype 1 Individuals on Methadone Maintenance in Rhode Island, U.S.A. International Symposium on Hepatitis Care in Substance Users, September 24-25, 2009, Zurich, Switzerland.
5. **Zaller N**, McKenzie M, et al. Initiation of Methadone During Incarceration and Linkage to Treatment Upon Release: Results of a Randomized Control Trial. Academic Correctional Health Conference, December 3-4, 2009, Ft. Lauderdale, FL.
6. **Zaller N**, McKenzie M, et al. Initiation of Suboxone During Incarceration and Linkage to Treatment Upon Release. Academic Correctional Health Conference, December 3-4, 2009, Ft. Lauderdale, FL.
7. **Zaller N**, Jeronimo A, et al. Pharmacist and Pharmacy Staff Experiences with Non-Prescription (NP) Sale of Syringes and Attitudes Toward Providing HIV Prevention Services for Injection Drug Users (IDUs) in Providence, RI. 8<sup>th</sup> National Harm Reduction Conference November 18-21, 2010. Austin, TX.
8. **Zaller N**, Yokell M, et al. Injection Drug Users' (IDUs) attitudes and experiences regarding pharmacy-based health interventions. 2011 National HIV Prevention Conference August 14-17, 2011. Atlanta, GA.
9. Ramos K, Yokell M and **Zaller N**. A Meta-Analysis of HIV Prevention Interventions. 2011 Addiction Health Services Research Conference. October 3-5, 2011. Fairfax, VA.
10. **Zaller N**. Opiate Replacement Therapy in Corrections: Past, Present and Future. 4<sup>th</sup> Annual Healthcare Conference on Correctional Health. March 10-12. Worcester, MA.

## GRANTS

Fogarty International Center/USNIH: Grant # 2 D 43 TW000010-17-AITRP. Fogarty International AIDS Research and Training Program \$61,059, 04/03-03/04, PI.

United Way of Rhode Island Special Opportunity Grant, \$15,000, 12/06-07/07, PI

The Drug Policy Alliance Promoting Policy Change \$20,000, 2007-, PI

Lifespan/Tufts/Brown Center for AIDS Research (CFAR) Developmental Grant, P30 AI042853, \$40,000 2008-2009, PI

Open Society Institute (OSI) Closing the Addiction Treatment Gap Initiative, \$600,000, 2008-2011, PI

National Institute of Drug Abuse (NIDA) Feasibility of Pharmacy-Based HIV Interventions among IDUs: 2 New England Cities. R21DA02501, 64,030, sub-(only) 8/1/2009-1/31/2011, site PI

#### UNIVERSITY TEACHING ROLES

Johns Hopkins Bloomberg School of Public Health (2002), Case Studies in Primary Health Care (15 students)

Johns Hopkins Bloomberg School of Public Health (2002, 2003), Public Health Problem Solving (15 students)

Xinjiang University Medical School (2004), Introduction to Epidemiology (25 students)

Brown University School of Medicine (2008-), Case Control Methodology Session for the Community Health Clerkship (6-10 students)

Rhode Island College (2011-), Drugs, Society and Chemical Dependency (30 students)

#### JOURNAL REFEREE

*Drug and Alcohol Dependence*

*Vox sanguinis*

*Journal of Opioid Management*

*Journal of Urban Health*

*BMC Health Services Research*



*International Journal of Equity and Health*  
*American Journal of Public Health*  
*Journal of Healthcare for the Poor and Underserved*  
*AIDS and Behavior*  
*BMC Public Health*  
*Pharmacy Practice*  
*Journal of American Pharmacist Association*

GRANT REVIEW COMMITTEES

Robert Wood Johnson Foundation  
Substance Abuse Policy Research Program

LANGUAGE SKILLS

English, Native Speaker  
Mandarin Chinese, Fluent